Guan Ying, Li Anchuan, Xiao Weiwei, Liu Shuai, Chen Binbin, Lu Taixiang, Zhao Chong, Han Fei
Department of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China.
Department of Radiation Oncology, Affiliated Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China.
Oncotarget. 2015 Oct 20;6(32):33926-34. doi: 10.18632/oncotarget.5271.
To evaluate the short-term efficacy and safety of recombinant human endostatin (Endostar) combined with chemoradiotherapy for the treatment of advanced, locally recurrent nasopharyngeal carcinoma (NPC).
Between March 2010 and October 2013, a total of 22 patients with stage rIII-IVb locally recurrent NPC underwent salvage radiotherapy with Endostar in Sun Yat-Sen University Cancer Center. Intensity-modulated radiotherapy (IMRT) was delivered. Platinum-based chemotherapy was used in a neoadjuvant protocol. Endostar was continuously administered intravenously (105 mg/m2) for 14 days (Days 1-14) from the first day of treatment during a 21-day cycle. Tumor response and treatment toxicities were observed.
Until January 2014, the median follow-up time was 13 months (range, 4-41 months). All patients completed the planned radiotherapy. A complete response was achieved in 20 patients, and a partial response was achieved in 2 patients. The incidence of grade 3-5 late radiation injury in this study was 50% (11/22) and that of nasopharyngeal mucosal necrosis was 31.8% (7/22).
Endostar combined with chemoradiotherapy may be effective in decreasing both the incidence of nasopharyngeal mucosal necrosis. Studies with a larger sample size and longer follow-up are warranted.
评估重组人血管内皮抑素（恩度）联合放化疗治疗局部晚期复发性鼻咽癌（NPC）的短期疗效和安全性。
2010年3月至2013年10月，中山大学肿瘤防治中心共有22例rIII-IVb期局部复发性NPC患者接受了恩度挽救性放疗。采用调强放疗（IMRT）。铂类化疗用于新辅助方案。从治疗的第一天开始，在21天的周期内连续14天（第1-14天）静脉注射恩度（105mg/m²）。观察肿瘤反应和治疗毒性。
截至2014年1月，中位随访时间为13个月（范围4-41个月）。所有患者均完成了计划的放疗。20例患者达到完全缓解，2例患者达到部分缓解。本研究中3-5级晚期放射损伤的发生率为50%（11/22），鼻咽黏膜坏死的发生率为31.8%（7/22）。
恩度联合放化疗可能有效降低鼻咽黏膜坏死的发生率。有必要进行更大样本量和更长随访时间的研究。
